Occam Places Mark McDonough as CEO of ChromaCode
ChromaCode, a private, California-based molecular diagnostics company with founders out of Illumina, Google[x], and Luminex, has appointed Mark McDonough as CEO. Investors include NEA, Northpond Ventures, Vensana Capital, and Adjuvant Capital.
Mark is an accomplished, commercially-oriented serial CEO with more than two decades of achievement in molecular diagnostics. Most recently, he was CEO of PierianDx, a private, genomic SaaS solution provider in the cancer diagnostic space. Earlier, Mark served as CEO of CombiMatrix, a public company and leader in high-complexity reproductive health testing. He orchestrated that company’s sale to Invitae in 2017.
This is Occam’s second Dx CEO placement in a matter of months. Last year, Dave Mullarkey was appointed CEO of ClearNote Health, a Stephen Quake company.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.